NEW YORK–(BUSINESS WIRE)–Treadwell Therapeutics, a clinical-stage biotechnology company developing novel therapeutics for highly aggressive cancers, today announced that members of the management team will provide a business overview and update at the Jefferies Virtual Healthcare Conference at 4:30 pm ET on Thursday, June 4, 2020.
A live webcast of the presentation will be available through the Company’s website at www.treadwelltx.com. Following the live webcast, an archived replay will be available on the Company’s website.
About Treadwell Therapeutics
Treadwell Therapeutics is a clinical-stage oncology company exploiting cancer cells’ vulnerabilities to develop first-in-class and best-in-class small molecules to address unmet needs in patients with cancer. The Company’s robust, internally developed pipeline includes a first-in-class PLK4 kinase inhibitor, CFI-400945 and a potentially best-in-class TTK inhibitor, CFI-402257 ready for Phase 2, and CFI-402411, an oral immunomodulatory kinase inhibitor with activity toward HPK1, which will enter the clinic in 2020. For more information, please visit www.treadwelltx.com.
Stern Investor Relations, Inc.